Matt Gevaert is the visionary CEO and Founder of KIYATEC, Inc., a groundbreaking company that has been at the forefront of disrupting cancer paradigms through functional precision oncology. With over 16 years of experience leading KIYATEC, Matt has been instrumental in developing innovative 3D cell culture technology platforms that measure the response of live cancer cells from individual patients. This technology, used in clinical testing for various types of cancer, has the potential to revolutionize precision medicine and improve patient outcomes.

Matt’s academic background includes a PhD in Bioengineering from Clemson University, and he has held previous roles such as Technology Commercialization Officer at the Clemson University Research Foundation, where he led the commercialization of biomedical sciences and biotechnology intellectual property. He is also a successful fundraiser within South Carolina’s nascent investment ecosystem and is a prolific inventor with over 30 patents, peer-reviewed publications, and conference abstracts to his name.